Recently, the administration of the anti-inhibitory KIR antibody IPH2101 to autologous multiple myeloma (MM) cells enhanced NK cell cytotoxicity against the tumor cell but not normal cells by blocking the interaction of KIR2DL1–3 with HLA-C [81,82]. Here, KIR3DL1 is linked to neoplasm.